A vaccine revolution. Where do we begin?Leave a Comment
EAVI2020 coordinator, Prof Robin Shattock lead the recent Imperial Global Science Policy Forum which focussed on global challenges surrounding vaccines and the latest research in vaccine technology.
EAVI coordinator, Prof Robin Shattock presented at the recent Imperial Global Science Policy Forum in May 2019; a high-profile network which hosts a programme of events focussing on some of the most important global challenges. The theme for this iteration focussed on contemporary challenges of vaccine development.
“Vaccination is one of the most effective medical interventions ever introduced”Prof. Robin Shattock
As director of the Future Vaccine Manufacturing Research (FMV) Hub, which is looking to transform how we manufacture vaccines for developing countries, Robin spoke about the main challenges in the current landscape, which include antibiotic resistance, cost of manufacturing, and public awareness and push back. This led to a mapping of the strategies FMV Hub have put in place to tackle these challenges. He detailed how a revolutionary model of vaccine development and distribution – a hub-and-spoke model as a simplified description – will produce benefits and impact from global to local levels.
“Rise in antibiotic resistance is increasingly becoming a problem”.Prof Robin Shattock
Robin was joined by fellow researchers from Imperial also bringing forth their innovative studies to vaccine development, Professor Wendy Barclay from Virology and Professor Jason Hallet from Natural Resource Engineering. The presentations were delivered in PechaKucha format; a simple presentation style where the images advance automatically after 20 seconds and presenters talk along to the images. This was effective and connected the audiences to the content and to each speaker.
“Vaccine discovery and development is a very risky business…[but] we are already beginning to make a difference in vaccine technology”Prof Robin Shattock
Robin thus gave a speedy but succinct 6-minute presentation on the establishment of international collaborations aimed to accelerate the search for an effective HIV vaccine. Much like the work going on in EAVI2020 this involves preclinical identification, development and selection of HIV microbicide and vaccine candidates.
Go to the website for more information on the strategies, impact and benefit of the Future Vaccine Manufacturing Research (FMV) Hub.